1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (5413)
  2. Journal Article (5194)
  3. Review (307)
  4. Book Section (177)
  5. Editorial (144)
  6. Research Letter (114)
  7. Guidelines (66)
  8. Conference Paper (60)
  9. Correspondence (44)
  10. Miscellaneous (14)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (11542)
  2. Department of Medicine (11500)
  3. Center for Hematologic Malignancies (9298)
  4. GSK Faculty (4034)
  5. Adult Leukemia (3229)
  6. Sloan Kettering Institute Faculty (2526)

More Groups

People
  1. Sergio Giralt (906)
  2. Miguel-Angel Perales (771)
  3. Andrew Zelenetz (717)
  4. Ross Levine (705)
  5. Martin Tallman (634)
  6. Steven Horwitz (577)

More People

Years
  1. 2023 (382)
  2. 2022 (964)
  3. 2021 (873)
  4. 2020 (934)
  5. 2019 (921)
  6. 2018 (787)

More Years

Publications
  1. Blood (2981)
  2. Journal of Clinical Oncology (1040)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Haematologica (258)
  5. Clinical Lymphoma, Myeloma and Leukemia (237)
  6. Cancer Research (224)

More Publications

Publishers
  1. American Society of Hematology (3161)
  2. Elsevier Inc. (1404)
  3. American Society of Clinical Oncology (1087)
  4. Nature Publishing Group (857)
  5. American Association for Cancer Research (587)
  6. Wiley Blackwell (401)

More Publishers

Results (11542)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Risk of MGUS, a multiple myeloma precursor, in relation to food and beverage intake in the National Health and Nutrition Examination Survey (NHANES)
    Meeting Abstract

    Joseph, J.; Tang, L.; Hillengass, J.; Landgren, O.; Usmani, S. Z.; Lesokhin, A. M.; Moysich, K. B.; Shah, U. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1
    Meeting Abstract

    Tomasson, M. H.; Bahlis, N. J.; Costello, C.; Raje, N. S.; Levy, M. Y.; Dholaria, B. R.; Solh, M. M.; Damore, M. A.; Jiang, S.; Xie, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study update
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Vij, R.; Escalante, F.; Delforge, M.; Kotowsky, N.; Bitetti, J.; Boytsov, N.; Camadoo-O'Byrne, L.; Powers Happ, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Dreyling, M. H.; Gaidano, G.; González Barca, E.; Jurczak, W.; Maddocks, K. J.; Menne, T.; Tournilhac, O.; Bakuli, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Predictors of resistance to trastuzumab deruxtecan (T-DXd) in esophagogastric adenocarcinoma (EGC)
    Meeting Abstract

    Tsai, C.; Chou, J. F.; Biachi de Castria, T.; Tang, L. H.; Ilson, D. H.; Ku, G. Y.; Schultz, N.; Capanu, M.; Janjigian, Y. Y.; Maron, S. B.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study
    Meeting Abstract

    Passamonti, F.; Patriarca, A.; Knapper, S.; Rivera, C.; Scandura, J.; Devos, T.; Granacher, N.; Mead, A. J.; Oh, S.; Palmer, J. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis
    Meeting Abstract

    Ajufo, H.; Bewersdorf, J. P.; Harrison, C.; Palandri, F.; Mascarenhas, J.; Palmer, J. M.; Gerds, A. T.; Kiladjian, J. J.; Derkach, A.; Rampal, R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3
    Meeting Abstract

    Shah, B. D.; Cassaday, R. D.; Park, J. H.; Houot, R.; Oluwole, O. O.; Logan, A.; Boissel, N.; Leguay, T.; Bishop, M. R.; Topp, M. S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study
    Meeting Abstract

    Roddie, C.; Sandhu, K. S.; Tholouli, E.; Shaughnessy, P.; Barba, P.; Guerreiro, M. N.; Yallop, D.; Abedi, M.; Chaganti, S.; Ghobadi, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Real-world treatment patterns, healthcare resource utilization (HRU) and costs for relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Chimeric antigen receptor T-cell (CAR T) and monoclonal antibodies (MAB) therapies
    Meeting Abstract

    Feng, C.; Murphy, L.; Engel-Nitz, N.; Nguyen, A.; Patel, A.; DuCharme, M.; Fu, C.; Shah, G.
    Value in Health (2023)

    Fulltext@MSK | Save